#Camlinfinesciences Q3 2022 Concall Highlights 🧪🧪

Like & Retweet for better reach !

Operational Highlights

1. Revenue grows QoQ grows by 22.4% to ₹380Cr fuelled by robust demand
2. Gross margin improves by 166 bps QoQ to 46.7% despite the inflationary trend in raw material and logistic costs

3. EBITDA margin improves by 719 bps QoQ to 14.5%

4. Sustained performance despite annual maintenance shut down in Diphenol Plant in Europe
Revenue split

1. Shelf life: 31%, Blends: 32%, Performance chemicals: 36% ,Aroma chemical: 1%

Operational Highlights

1. Lockheed martin deal production will start from FY24
2. Substantial breakthrough in feed additive business and focus to expand business in north and central America geographies
3. Entering in geographies of Ecuador for aquatic market

4. 4-5 new products to be introduced in new feed additives business segment with revenue potential of ₹250-300 Cr in 3-4 years
5. Catechol is having limited induce and hydroquinone is facing challenges in demand and expected to continue further

6. Price pass on is partially done in hydroquinone, rest of the pass on will be done in upcoming qtrs
7. For CFS North America, revenue is expected to stay at break even until FY23

8. Evaluating options to manufacture MEHQ from anisole

9. 17-20% EBITDA margins sustainable post vanillin capex
10. Pricing is now done on a quarterly basis. 80% of business is direct consumer driven and rest 20% is distributor driven
CSF regional breakup

1. India- Revenues stood at ₹200Cr with growth of 22% YoY
2. Mexico- Revenues stood at ₹91.3Cr with growth of 29% YoY
3. Europe- Revenues stood at ₹87.4Cr with growth of 26% YoY
4. Brazil- Revenues stood at ₹22.1Cr with growth of 21% YoY
5. North America- Revenues stood at ₹13.4Cr with growth of 68% YoY
Capex

1. CAPEX program on track with Ethyl / Methyl Vanillin
at Dahej SEZ expected to achieve mechanical completion in March 2. 2022 and commercial production in June / July 2022
3. ₹30-40Cr capex for new business segments i.e. feed additives.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Feb 11
#SRF Q3 Concall Highlights 🧪🧪

Like & Retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹3,345.9 as against ₹2146.4 Cr in Q3FY21, translating growth of 55.9% YoY

2. EBITDA margins stood at 25.7%
Revenue breakup

Chemical business-42.6%, Packaging films-38.1%, Technical textile- 16.1% and others-3.2%
Business Highlights

1. Launched new pharma intermediate during the quarter and successfully conducted campaigns for 2-3 upcoming products.

2. Achieved highest ever production in key products and are constantly enhancing capacity utilisation at newly commissioned facility
Read 16 tweets
Feb 11
#Aartiindustries Q3 concall highlights

Like & Retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY

2. Both the Pharmaceuticals & Specialty Chemicals segment outperformed during the quarter
3. Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics costs
4. Accrual of termination fees in respect of the long-term contract of ₹631 crores resulting in higher revenues. As a result, EBITDA includes ₹611 Crs during the quarter.
Read 18 tweets
Feb 11
#SHKelkar Q3 2022 Concall Highlights

Like & Retweet for better reach !

Operational Highlights

1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375.4 crore in Q3FY21, higher by 5.6%
2. EBITDA margins remained stable on a sequential basis at 15.8% translating to EBITDA of 63.8 crore

3. Gross margins in 9M FY22 stood at 41.4%

4. Q3 FY22 revenues growth was driven on the back of rebound in consumer demand led by discretionary items and new client wins.
5. While the domestic core fragrance segment delivered healthy performance, sales in Southeast Asia region continued to be affected by the Covid surge and is yet to recover
Read 19 tweets
Feb 11
#AurobindoPharma Q3 FY22 concall highlights 💊💊

Like & retweet for better reach !

1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).

4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
Read 18 tweets
Feb 11
#HesterBiosciences Q3 FY22 concall highlights 🐓🐓

Like & Retweet for better reach !

1. Revenues are flat and profitability is down because of the high base effect.
2. Q3 and Q4 of FY21 were phenomenal quarters for the company because there was a major poultry disease outbreak which led to increased demand for vaccines.

3. They also have additional income every year from licensing fees which is not there in Q3 FY22.
4. They have been working on 3 vaccines - classical swine fever, lumpy skin disease and sheep pox vaccine. All these vaccines are in the final stages of quality testing and regulatory approval and they hope to launch them in Q1 FY23.
Read 14 tweets
Feb 11
#AlembicPharma Q3 FY22 concall highlights

Like & Retweet for better reach !

1. Revenues for the quarter stood at ₹1272 Cr (3% decline YoY).

2. EBITDA for the quarter was ₹269 Cr (33% decline YoY). EBITDA margin was at 21% for the quarter.
3. PAT stood at 176 Cr (40% decline YoY).

4. They believe the price erosion in the US business has normalized and they can grow with new launches from here on.
5. They have a couple of first-to-file launches coming up in FY23.

6. R&D expenditure for the quarter was at ₹154 Cr which is about 12% of sales. They have filed 6 ANDAs during the quarter.
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

:(